Table 2.
Tumour Type | Essential Result of the Studies | CB1 | CB2 | FAAH | MAGL | Reference |
---|---|---|---|---|---|---|
Breast cancer | No correlation of FAAH expression with disease-specific survival, but levels of FAAH significantly increased in patients with higher number of axillary lymph node metastases | ↔ | [45] | |||
Strong association between higher CB2 protein expression in HER2+ breast tumours and lower patient overall, relapse-free and metastasis-free survival | ○ | [47] | ||||
High HER2–CB2 heteromer expression associated with lower disease-free and overall patient survival | ○ | [48] | ||||
Colorectal cancer | Higher CB1 expression correlated with poorer overall survival in stage IV; CB1 expression not correlated with patient survival following surgery in stage I/II or III cancer | ○ | [54] | |||
CB2 mRNA expression as prognostic factor for colon but not for rectal cancer; five-year overall survival for patients without CB2 expression was 76.16% versus 41.94% for patients with CB2 expression | ○ | [55] | ||||
Higher levels of MAGL or lower levels of CB2 in tumour-associated macrophages of patients with colorectal cancer associated with better survival | ○ | ○ | [57] | |||
Esophageal squamous cell carcinoma | Overexpression of CB1 in esophageal squamous cell carcinoma correlated with metastasis to lymph nodes and distant organs, and poor prognosis | ○ | [64] | |||
Head and neck squamous cell carcinoma | Higher CB2 receptor expression associated with reduced disease-specific survival; CB1 receptor immunoreactivity not associated with survival | ↔ | ○ | [68] | ||
Hepatocellular carcinoma | Disease-free survival in patients with hepatocellular carcinoma with high CB1 and CB2 expression significantly better than in patients with low expression | ○ | ○ | [69] | ||
MAGL low-expression group with significantly better survival than MAGL high-expression group | ○ | [71] | ||||
Clinical prognosis for the MAGL high group markedly poorer than that for the MAGL low group in the 1-, 3-, and 5-year overall survival times and recurrence rates | ○ | [72] | ||||
Lung cancer | Lung adenocarcinoma patients with high CB2 level showed a shorter overall survival | ○ | [75] | |||
Patients with high expression levels of CB1, CB2 and CB1/CB2 showed increased survival | ○ | ○ | [76] | |||
Overall survival gradually reduced with increasing ABHD6 levels; no significant association with MAGL expression | ↔ | [77] | ||||
High MAGL expression associated with worse outcomes | ○ | [78] | ||||
Mobile tongue squamous cell carcinoma | High CB1 and CB2 expression associated with longer overall and disease-free survival times | ○ | ○ | [83] | ||
Pancreatic cancer | Correlation between longer survival and low CB1 receptor or high FAAH as well as MAGL levels; no correlation between survival and CB2 immunoreactivity | ○ | ↔ | ○ | ○ | [86] |
Prostate cancer | High CB1 expression associated with a shorter survival time | ○ | [89] | |||
High tumour epithelial FAAH associated with a poor disease-specific survival | ○ | [91] | ||||
Renal cell carcinoma |
Higher CB2 expression tending to have poor clinical outcomes in survival analyses | ○ | [95] |
○, higher expression is associated with poorer survival (or vice versa: lower expression is associated with prolonged survival); ○, lower expression is associated with poorer survival (or vice versa: higher expression is linked with prolonged survival); ↔, no association of the indicated parameter with patients’ survival; CB1, CB2, cannabinoid receptor 1 or 2; FAAH, fatty acid amide hydrolase; HER2, human epidermal growth factor receptor 2; MAGL, monoacylglycerol lipase.